Explore the newest developments in clinical research and treatment for myelodysplastic syndromes (MDS). Cancer Nursing Today has the latest clinical findings and perspectives on personalized risk prediction models for MDS, genetic mutations related to MDS progression, donor lymphocyte infusions, and more. From clinical trials and screening techniques to the latest treatments, learn how MDS care is evolving.
Survival rates for myelodysplastic syndromes (MDS) varies widely – from months to decades – highlighting the need for prognostic systems that incorporate clinical, pathologic, and molecular data to predict survival more accurately in this patient group. In a study published in the Journal of Clinical Oncology, researchers sought to develop a prognostic model for patients with MDS receiving a variety of MDS-targeted treatments. First, they enrolled 1,471 patients with comprehensively annotated clinical and molecular data in a training cohort and analyzed data using machine learning techniques. They ...
The new data is being used to develop a biomarker tool to predict the efficacy of neoadjuvant pembrolizumab.
Many studies are examining COVID-19's impact on particular subgroups of patients with cancer.
Oncology nurses experience stress from many different directions—time pressures, nursing shortages, complex cancer ...